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Histone deacetylase (HDAC) inhibition is a novel entity in medical oncology, and several HDAC
inhibitors are in clinical trials. One of them is the hydroxamic acid belinostat (PXD101) that has
demonstrated therapeutic efﬁcacy for several clinical indications. Acetylation of histones is a key event
after treatment with HDAC inhibitors, and could thus be used as a marker for monitoring cellular
response to HDAC inhibitor treatment. Here we describe the utility of a newly described monoclonal
antibody against acetylated H4 for immunohistochemistry on parafﬁn-embedded ﬁne needle biopsies
from nude mice carrying A2780 human ovarian cancer xenografts. Acetylated H4 was monitored in
vivo by immunohistochemistry during treatment with belinostat, and compared with pharmaco-
kinetics in plasma and tumor tissue. We found an increased level of acetylated H4 15 min after a
single treatment (200 mg/kg i.v.) with maximum level reached after 1 h. H4 acetylation intensity
reﬂected the belinostat concentration in plasma and tumor tissue. The threshold level for belinostat
activity, indicated by acetylated H4, correlated with belinostat plasma concentrations above 1,000 ng/
ml. In conclusion, examination of H4 acetylation in ﬁne needle biopsies using the T25 antibody may
prove useful in monitoring HDAC inhibitor efﬁcacy in clinical trials involving humans with solid
tumors.
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ﬁne needle biopsy.
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Histone deacetylase (HDAC) inhibitors are a
promising group of anticancer agents that target
the group of HDAC enzymes reported to be in-
volvedincancerdevelopment(1–3).HDACslead
to transcriptional repression through alteration
of chromatin structure. Remodeling of chroma-
tin through modiﬁcations of histone molecules is
a key event in gene transcription (4). Histones
can be modiﬁed by acetylation, methylation,
phosphorylation, and ubiquitination (4, 5).
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Acetylation of histones is regulated by the op-
posite mechanisms of HDACs and histone
acetyltransferases (HATs). In general, histone
acetylation through HAT activity leads to in-
creasedtranscriptionalactivity,whereasdeacety-
lation through HDACactivity leads to transcrip-
tional repression (6, 7).
Treatment with HDAC inhibitors represses
HDAC activity and upregulates histone acety-
lation leading to transcription of genes involved
in cell cycle arrest, differentiation, and apoptosis
(8–11). Several HDAC inhibitors have proven ef-
ﬁcacy in clinical trials (12–18) and in OctoberMONITORING BELINOSTAT ACTIVITY
2006 the Food and Drug Administration (FDA)
approved the ﬁrst HDAC inhibitor ZOLIN-
ZATM (vorinostat, suberoylanilide hydroxamic
acid, SAHA) for treatment of patients with cu-
taneous T-cell lymphomas (http://www.fda.gov/
bbs/topics/NEWS/2006/NEW01484.html).
Histone acetylation is a deﬁning event after
treatment with an HDAC inhibitor, and can
thus be used as an indicator of HDAC inhibitor
activity in both normal and tumor cells. This
has led to the widespread use of histone acety-
lation in peripheral blood mononuclear cells
(PBMCs) as a surrogate marker in phase I clin-
ical trials (14, 18–21). However, it would obvi-
ously be an advantage to be able to monitor
acetylation in a solid tumor and correlate the
efﬁcacy of the HDAC inhibitor with concen-
trations found in plasma. This would provide a
valuable tool for investigating alternative sched-
ules and for optimizing the efﬁcacy of HDAC
inhibitors in the treatment of solid tumors.
In order to obtain a validated model for this
approach, we describe the utility of using a new
monoclonal antibody to H4 acetylation for im-
munohistochemistry, together with its applica-
bility in repeated ﬁne needle biopsies from
mouse xenograft solid tumors treated intra-
venously with the HDAC inhibitor belinostat
(PXD101). We further investigated to what ex-
tent the time course of H4 acetylation in tumor
tissue correlated with the belinostat concen-
tration in plasma.
MATERIALS AND METHODS
Cell lines
The following cell lines were purchased from
ATCC: HCT-116 human colon carcinoma (ATCC,
CCI-247), MCF-7 human breast carcinoma (ATCC,
HTB-22) and A549 human lung carcinoma (ATCC,
CCL-185). PC-3 human prostate cancer cell line
(ECACC, 90112714) was purchased from ECACC.
A2780 human ovarian carcinoma cell line was a gift
from R. Ozols, Fox Chase Cancer Center, Philadel-
phia, PA, and P388 murine leukemia cell line was a
gift from F.M. Shabel, Southern Research Institute,
Birmingham, AL.
Test of antibody speciﬁcity and reactivity
We used the novel mouse monoclonal anti-human
T25 antibody against acetylated histone H4 that rec-
ognizes acetylated Lys8 and Lys12 on H4 (22). West-
ern blotting using either whole cell lysates of HCT-
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116 cells or histones puriﬁed from P388 cells after
treatment with 1 mM belinostat for 1 h was used for
testing antibody speciﬁcity. Blots were incubated with
T25 antibody before development. The appearance
of only one band veriﬁed antibody speciﬁcity. The
reactivity of T25 was evaluated according to DAKO
standard IHC-procedures on different malignant tu-
mors (head and neck, cervix, brain, colon, stomach,
prostate, lymphomas, melanomas, lung, ovary, liver,
and breast) as well as on normal tissue (prostate, kid-
ney, pancreas, cerebellum, and tonsil).
Xenografts
Female NMRI nude mice (Taconic), 6–8 weeks of
age, were used for the xenograft models. Tumor cells
grown in cell cultures were trypsinized and ∂107 cells
(100 ml) were mixed with 100 ml matrigel. Mice were
anesthesized using Hypnorm/Dormicum, and cells
were injected subcutaneously into the ﬂank.
Immunohistochemistry
Formalin-ﬁxed and parafﬁn-embedded tumors and
biopsies were stained for H&E, p21 and acetylated
H4 by standard procedures. For examination of H4
acetylation and p21 expression, heat-induced epitope
retrieval was performed using TEG buffer pH 9 (10
mM Trisπ0.5 mM EGTA). Peroxidase Blocking Re-
agent (DAKO, S2001) was used for blocking endogen
peroxidase activity. Slides were pre-incubated in 2%
BSA in TBS pH 7.6, before primary antibody was
added. Primary antibodies were monoclonal anti-p21
(ab16767 [EA10], Abcam, dilution 1:80) and mono-
clonal anti-acetylated H4 (T25, Topotarget A/S, di-
lution 1:13,000). The antibodies were diluted in 2%
BSA in TBS pH 7.6. EnVisionπ (DAKO, K4001) and
DABπ (DAKO, K3468) were used as detection sys-
tem. Slides were counterstained with Mayer’s hema-
toxylin. Parafﬁn-embedded blocks of A2780 cells,
either untreated or treated with 1 mM belinostat for
1 h, were used as negative and positive control, re-
spectively (see Fig. 1). Slides were scored for staining
intensity, i.e. negative (scoreΩ0), weak (scoreΩ1),
moderate (scoreΩ2), or strong (scoreΩ3).
Extraction and analysis of belinostat in plasma and
tissue
Extraction procedures for plasma samples were
conducted to separate any tissue/protein from the
sample before analysis. The extractions were carried
out using Waters SiroccoTM Protein Precipitation
PlatesA with 96-well collection plates. First, 150 ml
internal standard (13-C-Belinostat) and 50 ml plasma
sample was added to each well and shaken on a vor-
texer. The loaded plate was centrifuged for 5 min,
2000 rpm. All liquid was evaporated under heated
nitrogen and the samples were re-dissolved in 100 ml
10% HCOOH in acetonitrile (ACN) (starting eluent)
before analysis.
Tumor and spleen samples were homogenized inMARQUARD et al.
Fig. 1. Parafﬁn-embedded blocks of A2780 ovarian cancer cells were used as controls in immunohistochemical
analysis of acetylated H4. (A) Untreated A2780 cells show no H4 acetylation and are used as negative control. (B)
A2780 cells treated with 1 mM belinostat for 1 h show strong H4 acetylation and are used as positive control.
400 ml homogenization buffer (25:25:25 Water/ACN/
Methanol with internal standard, 13-C-Belinostat 1
mg/ml) using an Ultra TuraxA mechanical homogen-
izer. Samples were then centrifuged at 5000 rpm for
5 min and 150 ml supernatant was removed and kept
for analysis.
Quantitative analysis of plasma, tumor and spleen
samples was done by liquid chromatography tandem
mass spectrometry using Waters UPLCA with re-
versed-phase analytical column (Acquity C18, 2.1¿50
mm, 1.7 mm particle size). A 5 min gradient using
0.05% HCOOH and ACN as mobile phase A and B,
respectively, was used with a ﬂow of 0.5 ml/min. All
data were processed using MassLynx 4.1.
Experiment 1: Monitoring the effect of HDAC
inhibitor treatment in vivo in different xenograft
models
The effect of belinostat in vivo was tested in a num-
ber of different xenograft models (PC-3, HCT-116,
MCF-7, A549 and A2780) in order to select a model
for biopsy sampling. Mice were treated with 100 mg/
kg belinostat or vehicle control (L-arginine 200 mg/
kg in isotonic sterile saline). After 1 h, mice were sac-
riﬁced and tumors were excised and prepared for im-
munohistochemistry.
Experiment 2: Collection of tumor biopsies and
inﬂuence on H4 acetylation
Tumor biopsies were collected by insertion of an
18G needle into the tumor tissue and carefully aspir-
ating while rotating the needle. It was investigated
whether the biopsies taken were representative for the
whole tumor and whether the method for biopsy col-
lection had any inﬂuence on H4 acetylation. Mice
with HCT-116, A2780, PC-3, or MCF-7 tumors were
treated with belinostat, 100 mg/kg, and after 1 h they
were sacriﬁced, tumor biopsies were collected, and
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biopsies and remaining tumor tissue were prepared
for immunohistochemistry. For the A2780 model, the
effect of repeated biopsy sampling was also investi-
gated. The mice were anesthetized by isoﬂurane in-
halation while tumor biopsies were collected.
Experiment 3: Time dependence of belinostat
treatment on H4 acetylation in solid tumor
The A2780 tumor model exhibited a limited
amount of necrosis, and this model was thus selected
for further investigation of the relationship between
exposure time and H4 acetylation in tumor tissue.
Furthermore, the expression of p21 was examined to
investigate a possible correlation between H4 acety-
lation and activation of gene transcription. 16 mice
with either small (300–400 mg) or large (1500–1800
mg) A2780 tumors were treated with 100 mg/kg beli-
nostat i.v. at time zero. One pretreatment (only large
tumor) and one post-treatment biopsy were collected
from the mice. Biopsies were collected at different
time points from 1 to 6 h after treatment, as de-
scribed in Table 1. At sacriﬁce (3, 6, or 24 h) the
entire tumor was removed. Sets of biopsies and corre-
sponding tumors were prepared for immunohisto-
chemistry.
Experiment 4: Relationship between H4 acetylation
in solid tumor and belinostat in plasma, tumor and
spleen tissue
Groups of 3–4 mice with subcutaneous A2780
xenografts were treated with 200 mg/kg¿1 belinostat
i.v. or vehicle control (L-arginine 400 mg/kg in iso-
tonic sterile saline) at time zero. After 15 min to 3
h, mice were sacriﬁced and plasma (lithium heparin
stabilized), tumor, and spleen tissue were collected.
Spleen and tumor were divided into two and prepared
for analysis for belinostat content and H4 acetylation
by IHC analysis. The degree of H4 acetylation wasMONITORING BELINOSTAT ACTIVITY
TABLE 1. Collection of biopsies for monitoring the effect of belinostat treatment (Experiment 3)
Large tumors (1500–1800 mg)
A2780 Pretreatment biopsy PXD101 exposure Whole tumor
ID (h) biopsy (h)
235 X 1 3
234 X 1 3
226 X 2 3
365 X 2 3
232 X 3 3
233 X 6 6
553 X 6 6
Small tumors (300–400 mg)
A2780 Pretreatment biopsy PXD101 exposure Whole tumor
ID (h) biopsy (h)
227 1 3
238 1 3
237 2 3
231 2 3
225 3 3
236 3 3
228 1 6
230 6 6
552 24
Seven mice with large A2780 tumors and nine mice with small A2780 tumors were included in the study. The
table shows time points for collection of biopsies and removal of whole tumors. Pretreatment biopsies were
collected only from mice with large tumors.
correlated with belinostat in plasma and tumor
tissue. The spleen representing peripheral blood
mononuclear cells (PBMCs) was included as refer-
ence tissue.
RESULTS
Reactivity of T25 anti-acetylated H4 antibody
The antibody T25 performed well in im-
munohistochemistry on formalin-ﬁxed parafﬁn-
embedded tissue samples with no background
staining; it showed nuclear labeling of epithelial
and cancer cells in all tested specimens. Stromal
cells showed no H4 acetylation. Acetylation of
H4 in cancer tissues is shown in Fig. 2.
Belinostat effect in different xenograft models
(Experiment 1)
The effect of belinostat on H4 acetylation
was tested in the PC-3, HCT-116, MCF-7, A549
and A2780 model. A single i.v. injection of 100
mg/kg caused H4 acetylation after1hi na l l
models. The strongest signal for H4 acetylation
was found in the A2780 ovarian cancer model,
followed by the HCT-116 colon cancer model
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and the A548 lung cancer model. Weak acety-
lation was seen in the PC-3 prostate cancer and
the MCF-7 lung cancer model (Fig. 3).
Collection of tumor biopsies and inﬂuence on H4
acetylation (Experiment 2)
Biopsies and corresponding solid tumor
(500–1000 mg) from A2780 (15 mice), HCT-116
(12 mice), PC-3 (6 mice), and MCF-7 (4 mice)
were compared to ensure that the biopsies taken
were representative for the whole tumor, and
that the models were suitable for biopsy collec-
tion.
All 15 biopsies collected from A2780 xeno-
graft mice contained tumor tissue with pre-
served or partly preserved morphology, and
only minimal necrosis. All 12 HCT-116 tumors
contained liquid necrosis in their center, and vi-
able tumor tissue was only observed in the peri-
phery of the tumor. Consequently, it was only
possible to collect a tumor tissue sample from 1
of 12 biopsies taken. All six PC-3 tumors con-
tained large necrotic areas and only one biopsy
contained tumor cells. Two of four biopsies
from MCF-7 tumors contained tumor tissue.MARQUARD et al.
Fig. 2. Nuclear expression of acetylated H4 in (A) breast and (B) liver carcinoma cells.
Fig. 3. H4 acetylation in vivo in different subcutaneous xenograft models 1 h after treatment with belinostat (100
mg/kg i.v.) (Experiment 1).
However, one of these biopsies contained ne-
crosis as well.
H4 acetylation was compared between the
biopsies and the representative tumors to ensure
that biopsy collection itself did not have an im-
pact on H4 acetylation. Of the 15 A2780 biop-
sies, 7 were treated with belinostat and the
staining proﬁle of acetylated H4 was similar in
tumors and representative biopsies. In contrast,
no or only weak H4 acetylation was observed in
A2780 tumors and biopsies from eight vehicle-
treated control mice. Examples of the staining
are found in Fig. 4A. It was also investigated
whether the repeated biopsy sampling had any
effect on acetylation in A2780 tumors. Even
though the repeat biopsies contained blood, this
did not interfere with the IHC staining or inter-
pretation of the results.
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Time dependence of belinostat treatment on H4
acetylation in solid tumor (Experiment 3)
The A2780 xenograft model was selected for
monitoring time dependence of belinostat effect
in vivo. 16 mice with either small (300–400 mg)
or large (1500–1800 mg) A2780 tumors were
treated with 100 mg/kg belinostat i.v. at time
zero. Pretreatment (only large tumors) and
post-treatment biopsies were collected from
mice after 1, 2, 3, or 6 h. At sacriﬁce the whole
tumor was excised.
22 biopsies from 16 mice were collected dur-
ing the study, and 21 of these biopsies contained
tumor tissue. Results of H4 acetylation are
shown in Table 2. Examples of staining are
shown in Fig. 4B. Pretreatment biopsies (nΩ7)
s h o w e dn o( n Ω1), weak (nΩ3) or moderate (nΩ
2) H4 acetylation. One pretreatment biopsy didMONITORING BELINOSTAT ACTIVITY
Fig.4.AcetylationofH4inA2780xenograftmicebeforeandafterbelinostattreatment.(A)AcetylatedH4infour
biopsies and their representative tumors (I–IV) (Experiment 2). No (I) or weak (II) H4 acetylation is observed in
vehicle control mice, whereas strong (III) or moderate (IV) H4 acetylation is observed 1 h after intravenous treat-
ment with belinostat (100 mg/kg) in both biopsies and tumors. (B) H4 acetylation in vivo in biopsies and tumor
from thesame mouseduring belinostat treatment(100 mg/kgi.v.) (Experiment3). The pretreatmentbiopsy shows
weak H4 acetylation, whereas strong H4 acetylation is seen 1 h after treatment. After 3 h, the H4 acetylation is
weak and has decreased to a level similar to that in the pretreatment biopsy.
not contain tumor tissue. All biopsies collected
1h( n Ω5 )a n d2h( n Ω4) after belinostat treat-
ment showed strong H4 acetylation; 3 h after
treatment strong acetylation was observed in
1/10 removed tumors as well as in 2 biopsies
from 3 of these tumors. The general ﬁndings at
3 h were weak or moderate acetylation similar
to the levels observed in the pretreatment biop-
sies. After 6 and 24 h, weak or no acetylation
was observed. Results of the p21 expression are
shown in Fig. 5. p21 showed strong nucleic ex-
pression in occasional cells from biopsies col-
lected pretreatment, and 1 and 2 h after treat-
ment. In addition, weak cytoplasmic expression
was observed in two of six pretreatment biopsies
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(33%), while one of four biopsies collected after
2 h showed moderate cytoplasmic expression
(25%). The cytoplasmic expression of p21 was
increased after 3 and 6 h, respectively. Thus, of
10 tumors removed after 3 h, 5 (50%) showed
weak expression, 2 (20%) showed moderate ex-
pression, and one (10%) showed strong expres-
sion. After 6 h, three of four tumors (75%)
showed moderate expression and one of four
(25%) showed strong expression. All biopsies re-
moved after 6 h showed moderate-to-strong
cytoplasmic expression as well. After 24 h, the
cytoplasmic expression had disappeared. In
contrast, nucleic staining was more pronounced
than in the earlier samples.MARQUARD et al.
TABLE 2. Results of H4 acetylation in A2780 biopsies and tumors during belinostat treatment in vivo
(Experiment 3)
A2780 H4 acetylation
Belinostat, 100 mg/kg i.v.
1h 2h 3h 3h 6h 6h 2 4h
ID Pretreatment biopsy biopsy biopsy biopsy tumor biopsy tumor tumor
Large tumors (1500–1800 mg)
235 Weak Strong Weak
234 Moderate Strong Moderate
226 Weak Strong Weak
365 Moderate Strong Moderate
232 Weak Strong Moderate
233 No No No
553 – Weak Weak
Small tumors (300–400 mg)
227 Strong Weak
238 Strong Moderate
237 Strong Strong
231 Strong –
225 Moderate Moderate
236 Strong Moderate
228 Strong Weak
230 Weak Weak
552 No
Strong H4 acetylation is observed in biopsies collected 1 and 2 h after treatment. In most samples, acetylation
is decreased after 3 h to a level similar to that observed in the pretreatment biopsies. Only weak acetylation is
observed 6 h after treatment. (–, missing).
Relationship between H4 acetylation in solid
tumor and belinostat levels in plasma, tumor and
spleen tissue (Experiment 4)
Mice with subcutaneous A2780 xenografts
(500–1000 mg) were treated with belinostat (200
mg/kg i.v.) or vehicle control and sacriﬁced after
15 min, 30 min, 1 h, 2 h, or 3 h for collection
of plasma, tumor and spleen for analysis of beli-
nostat content and staining for acetylated H4 in
tissue. The belinostat dose was increased from
100 to 200 mg/kg to increase the possibility of
detection of belinostat in tumor and spleen
tissue and to investigate whether the acetylation
Fig. 5. Expression of p21 in A2780 xenograft mice before and after belinostat treatment. p21 is observed in the
nucleus of occasional cells in samples collected pretreatment, and up to 3 h after treatment. Weak cytoplasmic
expression of p21 is observed 3 h after treatment and is strongly increased 6 h after treatment. The cytoplasmic
expression of p21 disappears after 24 h. However, the nucleic expression is now more pronounced.
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period could be extended beyond the 1–2 h
period observed in Experiment 3.
Analysis of belinostat in plasma, tumor and
spleen showed that its distribution to tumor and
spleen tissue was similar, and that tissue and
plasma distribution curves were parallel (Fig.
6). Thus, belinostat plasma concentration seems
to reﬂect the actual belinostat concentrations in
subcutaneous solid tumor tissue.
Results of H4 acetylation are shown in Table
3. After 15 min, weak-to-moderate acetylation
was observed in three of four tumors. Maximal
H4 acetylation levels were reached at 1 h, withMONITORING BELINOSTAT ACTIVITY
Fig.6.Belinostatinplasma(ng/ml),A2780subcutane-
ous tumor (ng/g) and spleen (ng/g) after intravenous
treatmentwith200mg/kgsingledoseat0min(Experi-
ment 4). The distribution of belinostat to tumor tissue
follows the plasma pharmacokinetic curve the ﬁrst 2 h
after treatment. After 3 h, the concentration of beli-
nostatinplasmaseemstodeclinemorethanthatinthe
tumor and spleen tissue. The distribution of belinostat
to subcutaneous solid tumor is comparable to the
spleen distribution.
four of four tumors showing strong H4 acety-
lation. After 2 h, one of three tumors showed
strong acetylation, but after 3 h, the acetylation
had decreased to weak and moderate levels.
Similar levels of H4 acetylation were observed
for spleen tissue (Fig. 7). No H4 acetylation was
detected in spleen and tumor tissue from vehicle
control mice. When correlating the plasma
pharmacokinetic proﬁle with H4 acetylation in
solid tumor tissue, the present study found that
belinostat activity, as indicated by the acetylated
H4 surrogate marker, was present as long as the
plasma concentration was above the 1000 ng/ml
level (Fig. 8). As belinostat plasma concen-
trations decrease, the H4 acetylation in tumor
tissue also declines.
DISCUSSION
Histone acetylation in PBMCs is often used as a
surrogate marker for HDAC inhibitor activity
andhasshownacorrelationwithplasmaconcen-
tration (19). Pharmacokinetic studies have
shown linear pharmacokinetics with dose pro-
portional increases in Cmax and AUC for vorino-
stat (12) and linear, dose-independent pharma-
cokinetics for MS-275 (18). Although time to
Cmax has shown similarity between different
HDAC inhibitors (Cmax reached after 1–2 h),
there have been large variations in the terminal
half-life between HDAC inhibitors (ranging
from 21 min to 74 h) (12, 14, 18, 23).
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Evaluation of ﬁve cell lines grown as xeno-
grafts on nude mice revealed differences in their
utility as biopsy models (Experiments 1 and 2),
which was probably due to differences in the
necrotic tendency of the tumors. PC-3 and
MCF-7 tumors showed less acetylation after 1
h compared to A2780 tumors. It is unknown
whether this difference in acetylation is due to
decreased efﬁcacy of the drug in certain tissues
or due to differences in cell viability. The PC-3,
MCF-7, and HCT-116 model contained necrotic
and ﬂuid areas, which hindered biopsy collec-
tion. Biopsies from A2780 tumors contained vi-
tal tumor tissue, making this a more suitable
model. In addition, A2780 biopsies were repre-
sentative of the tumors regarding level of H4
acetylation. Our initial studies showed that the
method of biopsy collection had no inﬂuence on
histone acetylation.
H4 acetylation was detected in tumor tissue
15 min after belinostat treatment and the maxi-
mum level was reached after 1 h. In a previous
study, increased H4 acetylation was found in pe-
ripheral canine blood 10 min after i.v. infusion
of belinostat given over 45 min (total dose 50
mg/kg) (24). In addition, the investigators found
increased H4 acetylation 30 min after treatment
with 1 mM belinostat in histones extracted from
A2780 cells (24). We observed that two biopsies
collected after 3 h showed stronger acetylation
than the corresponding tumors. Staining of the
tumors was uneven with weaker acetylation in
the middle than in the periphery. This problem
might be a result of insufﬁcient ﬁxation or too
short epitope retrieval of the tumors. Neverthe-
less, our results showed that H4 acetylation
reached base line level 3 h after treatment. Simi-
larly, Plumb et al. found that H4 acetylation
had returned to base line levels in histones ex-
tracted from A2780 cells and peripheral blood
from A2780 xenografts 3 h after treatment with
belinostat (1 mM or 40 mg/kg i.p.) (24). Our re-
sults from the monitoring study (Experiment 3)
showed different levels of H4 acetylation in pre-
treatment biopsies from different mice (Table 2),
which indicates that it is important to collect
pretreatment biopsies in order to have an inter-
nal control for baseline H4 acetylation.
In a clinical study, higher doses of the HDAC
inhibitor ZolinzaTM did not produce an increase
in extent of histone acetylation in peripheral
blood lymphocytes. Instead, the half-life ofMARQUARD et al.
TABLE 3. Results of H4 acetylation (score) in tumors and spleens from vehicle control mice or belinostat-treated
mice with A2780 xenografts (Experiment 4)
A2780 H4 acetylation
Belinostat, 200 mg/kg i.v.
ID Vehicle, 15 min 15 min 30 min 1 h 2 h 3 h
Tumor
270 No (0)
478 No (0)
282 No (0)
524 Weak (1)
277 Moderate (2)
531 Moderate (2)
296 No (0)
273 Moderate (2)
286 Moderate (2)
523 Strong (3)
527 Weak (1)
511 Strong (3)
283 Strong (3)
525 Strong (3)
508 Strong (3)
287 Moderate (2)
285 Strong (3)
522 Moderate (2)
532 Moderate (2)
295 Weak (1)
279 Moderate (2)
Mean 0 1.25 2 3 2.33 1.67
Spleen
270 No (0)
478 No (0)
282 No (0)
524 Moderate (2)
277 Moderate (2)
531 Weak (1)
296 Weak (1)
273 Strong (3)
286 Strong (3)
523 Moderate (2)
527 Moderate (2)
511 Strong (3)
283 Strong (3)
525 Moderate (2)
508 Strong (3)
287 Moderate (2)
285 Moderate (2)
522 Moderate (2)
532 Weak (1)
295 No (0)
279 Weak (1)
Mean 0 1.5 2.5 2.75 2 0.67
No H4 acetylation is observed in tissue from vehicle control mice. Weak-to-moderate acetylation is observed
after 15 min with maximal levels after 1 h. The levels of acetylation decrease after 2 h.
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Fig. 7. H4 acetylation score in tumor and spleen tissue
after treatment with belinostat, 200 mg/kg i.v. Maxi-
mal acetylation is observed 1 h after treatment. The
acetylation in spleen and subcutaneous tumor is com-
parable. A2780 xenograft, NMRI nude mice, 3–4
mice/time point.
Fig. 8. Overlay plot of belinostat concentrations in
plasma and H4 acetylation score in tumor tissue after
treatment with belinostat, 200 mg/kg i.v. Maximal
acetylation is observed 1 h after treatment, which co-
incides with belinostat plasma concentrations above
103 ng/ml. A2780 xenograft, NMRI nude mice, 3–4
mice/time point.
acetylated histones seemed to be increased (13).
In our study, increasing the dose from 100 to
200 mg/kg did not result in an extended acety-
lation period beyond the 1–2 h observed in Ex-
periment 3.
p21 was induced in the cytoplasm about 3 h
after belinostat treatment, and was further in-
creased after 6 h, where strong cytoplasmic ex-
pression was observed. Thus, p21 was induced
after acetylation of H4 was observed. H4 acety-
lation thus correlates with activation of gene
transcription after treatment with belinostat.
The cytoplasmic expression of p21 was de-
creased after 24 h. In contrast, p21 had relo-
cated to the nucleus. Cytoplasmic induction of
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p21 has previously been reported by O’Reilly et
al. (25). Here, the cytoplasmic induction was
observed in mice exposed to hyperoxia for 64 h.
We found comparable belinostat distribution
to tumor and spleen tissue, and in addition that
the distribution in tumor tissue followed the be-
linostat plasma pharmacokinetics. This indi-
cates that belinostat distribution is not tumor
speciﬁc and that plasma concentrations of beli-
nostat may be used to predict belinostat distri-
bution to solid tumor tissue. In the present
study, the belinostat concentration in plasma
and tumor correlated with levels of acetylated
H4 in the solid tumor tissue and PBMCs.
Acetylated H4 is a deﬁning event after treat-
ment with an HDAC inhibitor, and can thus be
used as an indicator of belinostat activity. We
found that H4 acetylation was present as long
as the plasma concentration was above 1000 ng/
ml. This supports that maintenance of beli-
nostat plasma levels above a certain level is re-
quired in order to achieve a prolonged effect of
belinostat treatment in solid tumors.
In conclusion, the monoclonal antibody T25
against acetylated H4 worked well on formalin-
ﬁxed parafﬁn-embedded tissue samples. The ef-
fect of belinostat on H4 acetylation using the
T25 antibody was evident 1 and 2 h after dos-
ing, with a return to baseline levels after 3 h.
H4 acetylation followed the belinostat concen-
tration in tumor tissue. Examination of H4
acetylation in ﬁne needle biopsies using the T25
antibody may thus prove useful in monitoring
HDAC inhibitor efﬁcacy in clinical trials involv-
ing solid tumors.
The technical assistance of Birgitte Jepsen is highly
appreciated.
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